[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Jiangmen Central Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":66},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,41],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100639094","phase-2-low-dose-thoracic-radiotherapy-followed-by-adebrelimab-plus-chemotherapy-and-then-sequential-maintenance-therapy-with-adebrelimab-for-extensive-stage-small-cell-lung-cancer-100639094",false,"NCT07583550","Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer","Efficacy and Safety of Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy and Sequential Adebrelimab Maintenance Therapy for Extensive-stage Small Cell Lung Cancer: A Prospective, Multicenter Phase II Study","Inclusion Criteria:\n\n1. Age ≥18 years and ≤75 years.\n2. Histologically or cytologically confirmed extensive-stage small cell lung cancer (SCLC).\n3. No prior systemic anti-tumor therapy.\n4. ECOG performance status 0-2 and life expectancy ≥12 weeks.\n5. At least one measurable lesion per RECIST version 1.1.\n6. No brainstem metastasis and no significant neurological symptoms from brain metastases.\n7. All participants must undergo routine contrast-enhanced CT of the chest and upper abdomen, as well as brain MRI, before enrollment. Whole-body PET-CT plus brain MRI is preferred. For participants with limited financial resources who also have significant obstructive pneumonia or atelectasis, an additional chest MRI is recommended.\n8. No malignant pleural effusion or pericardial effusion.\n9. All participants must provide written informed consent.\n\nExclusion Criteria:\n\n1. Presence of interstitial pneumonia or infectious fever prior to treatment.\n2. Comorbid autoimmune diseases or long-term oral corticosteroid use (including those who received oral corticosteroids within 14 days prior to treatment).\n3. Prior history of thoracic radiotherapy or thoracic surgery.\n4. Presence of Grade ≥3 hematologic toxicity or hepatic\u002Frenal impairment.\n5. Hypersensitivity to adebrelimab.\n6. Significant respiratory symptoms that preclude tolerance to radiotherapy.\n7. Active hepatitis B or hepatitis C infection with ongoing antiviral therapy. Subjects with a documented history of HBV infection who have achieved undetectable HBV levels after prior active treatment at the time of enrollment may be included.\n8. Presence of pleural effusion or pericardial effusion.","ALL","18 Years","75 Years",{"count":20,"type":21},43,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","This multicenter, prospective study aims to investigate the efficacy and safety of low-dose radiotherapy (15Gy\u002F1.5 Gy bid × 10 fractions) combined with 4-6 cycles of systemic chemotherapy plus anti-PD-L1 antibody, followed by anti-PD-L1 antibody maintenance for up to two years, in participants with extensive-stage small cell lung cancer (ES-SCLC).\n\nAdditionally, dynamic monitoring using next-generation sequencing (NGS) technology will be performed to assess ctDNA levels, genetic information, and mutation abundance at the following time points: before and after low-dose radiotherapy, after 4-6 cycles of chemotherapy plus anti-PD-L1 antibody (chemotherapy-immunotherapy), and before the initiation of anti-PD-L1 maintenance therapy. This approach aims to guide efficacy and prognosis prediction, as well as to identify potential biomarkers associated with treatment response.",[27,28],"Lung","Radiotherapy","NOT_YET_RECRUITING","2026-05-06",{"date":32,"type":33},"2026-05-13","ACTUAL",{"date":35,"type":21},"2026-05-01",{"date":37,"type":21},"2028-01-01",{"name":39,"class":40},"Jiangmen Central Hospital","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":50,"briefSummary":51,"conditions":52,"keywords":55,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":65,"locationsCount":4},"100630048","phase-2-furmonertinib-plus-radiotherapy-for-egfr-nsclc-with-pleural-effusion-100630048","NCT07482605","Furmonertinib Plus Radiotherapy for EGFR+ NSCLC With Pleural Effusion","A Prospective, Multicenter Study on the Safety and Efficacy of Furmonertinib Combined With Local Chest Radiotherapy in EGFR+ Non-small Cell Lung Adenocarcinoma Patients With Malignant Pleural Effusion","Inclusion Criteria:\n\n1. Age ≥ 18 years but ≤ 75 years;\n2. Histologically or cytologically confirmed advanced lung adenocarcinoma;\n3. Chest CT or whole-body PET-CT indicates pleural invasion with pleural effusion, and pleural fluid cytology confirms the presence of cancer cells. After 2 months of treatment with furmonertinib ± thoracentesis drainage, malignant pleural effusion is controlled (no pleural effusion or only ≤ 100 ml of pleural effusion), and a small amount of pericardial effusion may be present;\n4. No prior history of thoracic radiotherapy or thoracic surgery;\n5. Positive for EGFR-sensitive mutations (19del\u002FL858R);\n6. No prior systemic anti-tumor therapy;\n7. ECOG performance status 0-1, with a life expectancy of ≥ 12 weeks;\n8. At least one measurable lesion (according to RECIST 1.1);\n9. Signed informed consent obtained;\n10. No more than 3 bone metastases.\n\nExclusion Criteria:\n\n1. Complicated with interstitial pneumonia or infectious fever before treatment;\n2. Complicated with autoimmune diseases or long-term oral corticosteroid use;\n3. Prior history of thoracic radiotherapy or thoracic surgery;\n4. Complicated with severe anemia, grade 3 WBC or PLT suppression;\n5. Allergic to third-generation TKIs;\n6. Obvious respiratory symptoms, intolerant to radiotherapy;\n7. Active hepatitis B or hepatitis C infection, or currently undergoing antiviral treatment; patients with a clear history of HBV infection whose HBV DNA is at an undetectable level after previous active treatment may be enrolled;\n8. Poor control or continuous progression of pleural effusion after two consecutive months of TKI treatment;\n9. Patients with brain metastases or liver metastases.",{"count":49,"type":21},63,[24],"This study aims to prospectively and multi-centrally explore the efficacy and safety of furmonertinib combined with upfront thoracic radiotherapy in treating NSCLC participants with EGFR mutations and malignant pleural effusion, thereby providing more evidence-based medical evidence for improved diagnosis and treatment of NSCLC-MPE participants . Additionally, NGS testing of ctDNA from peripheral blood will be performed before the first furmonertinib treatment, before the first thoracic radiotherapy and after its completion, and after disease progression. This will help identify individuals who benefit from this treatment modality and investigate new resistance mechanisms to furmonertinib under the radiotherapy plus TKI combination model, ultimately serving participants better.",[53,54],"Lung Cancer (NSCLC)","Malignant Pleural Effusions (Mpe)- Pleurodesis",[56,28,57,58],"Furmonertinib","EGFR mutation","Lung adenocarcinoma","2026-03-18",{"date":61,"type":33},"2026-03-20",{"date":63,"type":21},"2026-03-01",{"date":37,"type":21},{"name":39,"class":40},""]